215 related articles for article (PubMed ID: 22724539)
1. Drug delivery systems for the topical treatment of cutaneous leishmaniasis.
Carneiro G; Aguiar MG; Fernandes AP; Ferreira LA
Expert Opin Drug Deliv; 2012 Sep; 9(9):1083-97. PubMed ID: 22724539
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous leishmaniasis treatment.
Minodier P; Parola P
Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
[TBL] [Abstract][Full Text] [Related]
3. Topical treatment of cutaneous leishmaniasis with novel amphotericin B-miltefosine co-incorporated second generation ultra-deformable liposomes.
Dar MJ; Khalid S; McElroy CA; Satoskar AR; Khan GM
Int J Pharm; 2020 Jan; 573():118900. PubMed ID: 31765786
[TBL] [Abstract][Full Text] [Related]
4. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
de Morais-Teixeira E; Aguiar MG; Soares de Souza Lima B; Ferreira LA; Rabello A
J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticles as multifunctional devices for the topical treatment of cutaneous leishmaniasis.
Moreno E; Schwartz J; Fernández C; Sanmartín C; Nguewa P; Irache JM; Espuelas S
Expert Opin Drug Deliv; 2014 Apr; 11(4):579-97. PubMed ID: 24620861
[TBL] [Abstract][Full Text] [Related]
6. Old world Leishmania infantum cutaneous leishmaniasis unresponsive to liposomal amphotericin B treated with topical imiquimod.
Hervás JA; Martín-Santiago A; Hervás D; Rojo E; Mena A; Rocamora V; Dueñas J
Pediatr Infect Dis J; 2012 Jan; 31(1):97-100. PubMed ID: 21829140
[TBL] [Abstract][Full Text] [Related]
7. Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis.
Jaafari MR; Hatamipour M; Alavizadeh SH; Abbasi A; Saberi Z; Rafati S; Taslimi Y; Mohammadi AM; Khamesipour A
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():156-165. PubMed ID: 31582344
[TBL] [Abstract][Full Text] [Related]
8. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
9. Can a simple outpatient-based treatment be used to treat cutaneous leishmaniasis in young children? A Critically Appraised Topic.
Burden-Teh E; Wootton CI; Williams HC
Br J Dermatol; 2015 Apr; 172(4):861-6. PubMed ID: 25354137
[TBL] [Abstract][Full Text] [Related]
10. Current scenario of drug development for leishmaniasis.
Croft SL; Seifert K; Yardley V
Indian J Med Res; 2006 Mar; 123(3):399-410. PubMed ID: 16778319
[TBL] [Abstract][Full Text] [Related]
11. Nanoemulsions containing amphotericin b and paromomycin for the treatment of cutaneous leishmaniasis.
Cunha NFC; de Siqueira LBO; Garcia AR; Rodrigues IA; Matos APDS; Júnior ER; Monteiro MSSB
Acta Trop; 2024 Jun; 254():107189. PubMed ID: 38522630
[TBL] [Abstract][Full Text] [Related]
12. Amphotericin B-loaded nanocarriers for topical treatment of cutaneous leishmaniasis: development, characterization, and in vitro skin permeation studies.
Santos CM; de Oliveira RB; Arantes VT; Caldeira LR; de Oliveira MC; Egito ES; Ferreira LA
J Biomed Nanotechnol; 2012 Apr; 8(2):322-9. PubMed ID: 22515084
[TBL] [Abstract][Full Text] [Related]
13. Current and emerging medications for the treatment of leishmaniasis.
Chakravarty J; Sundar S
Expert Opin Pharmacother; 2019 Jul; 20(10):1251-1265. PubMed ID: 31063412
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in amphotericin B delivery strategies for the treatment of leishmaniases.
Lanza JS; Pomel S; Loiseau PM; Frézard F
Expert Opin Drug Deliv; 2019 Oct; 16(10):1063-1079. PubMed ID: 31433678
[No Abstract] [Full Text] [Related]
15. Safety and efficacy of a combination of paromomycin and miltefosine for two vs. three courses in patients with post-kala-azar dermal leishmaniasis: an observational pilot study.
Pandey K; Pal B; Das VNR; Murti K; Lal CS; Verma N; Bimal S; Ali V; Verma RB; Topno RK; Siddiqi NA; Das P
Br J Dermatol; 2017 Aug; 177(2):557-559. PubMed ID: 27781268
[No Abstract] [Full Text] [Related]
16. Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, randomized trial in Isfahan, Iran.
Iraji F; Sadeghinia A
Ann Trop Med Parasitol; 2005 Jan; 99(1):3-9. PubMed ID: 15701249
[TBL] [Abstract][Full Text] [Related]
17. A phase II study to evaluate the safety and efficacy of topical 3% amphotericin B cream (Anfoleish) for the treatment of uncomplicated cutaneous leishmaniasis in Colombia.
López L; Vélez I; Asela C; Cruz C; Alves F; Robledo S; Arana B
PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006653. PubMed ID: 30044792
[TBL] [Abstract][Full Text] [Related]
18. Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model.
Van Bocxlaer K; Yardley V; Murdan S; Croft SL
J Pharm Pharmacol; 2016 Jul; 68(7):862-72. PubMed ID: 27230300
[TBL] [Abstract][Full Text] [Related]
19. Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis.
Abu Ammar A; Nasereddin A; Ereqat S; Dan-Goor M; Jaffe CL; Zussman E; Abdeen Z
Drug Deliv Transl Res; 2019 Feb; 9(1):76-84. PubMed ID: 30484256
[TBL] [Abstract][Full Text] [Related]
20. Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles.
Sousa-Batista AJ; Pacienza-Lima W; Ré MI; Rossi-Bergmann B
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():148-155. PubMed ID: 31331828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
